Matthew Seymour, MD: A Clinical Trialist’s Perspective

First International Summit on Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Nov

Today In Oncology

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Related Videos

Deborah Collyar: What's In It for Patients?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Local Consolidative Therapy Enhances Outcomes With Osimertinib in EGFR-Mutant NSCLC

Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib-Chemotherapy in EGFR-Positive NSCLC

Routine AI Assistance May Lead to Loss of Skills in Endoscopists, Study Shows

How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting

HER3-DXd in Patients With Active Brain Metastases From NSCLC and Breast Cancer